Eyenovia, Inc. — Form 10-Q Summary
Entity note: The supplied filing is for Eyenovia, Inc. (Nasdaq: EYEN), not Hyperion DeFi, Inc. It covers the quarter and nine months ended September 30, 2023; filed November 13, 2023. Eyenovia develops and commercializes ophthalmic products using its Optejet delivery system.
Business context and reporting period
Eyenovia received FDA approval for Mydcombi in May 2023 and began a targeted commercial launch on August 3. Its pipeline includes MicroPine for progressive myopia and MicroLine for presbyopia. The company also acquired exclusive U.S. commercialization rights to Formosa’s clobetasol ophthalmic product, then under FDA review.
Key financial metrics
| Metric | Three months ended September 30, 2023 | Nine months ended September 30, 2023 |
|---|---|---|
| Revenue | $1,198 | $1,198 |
| Gross profit | $0 | $0 |
| Research and development | $3.58 million | $8.91 million |
| General and administrative | $2.94 million | $9.03 million |
| Operating loss | $6.52 million | $17.94 million |
| Net loss | $7.34 million | $19.29 million |
| Basic and diluted loss per share | $0.18 | $0.50 |
| Cash used in operating activities | Not separately stated for the quarter | $17.51 million |
Cash and cash equivalents were $20.70 million at September 30, down from $22.86 million at December 31, 2022. Working capital was $19.98 million. Total assets were $34.87 million and stockholders’ equity was $15.78 million. Gross notes payable were $15.64 million, compared with $10.43 million at year-end; the balance sheet reports current and non-current notes net of discounts. Nine-month investing cash outflow was $3.83 million, and financing cash inflow was $19.18 million.
Material changes versus the prior comparable period
- Third-quarter revenue was only $1,198, with an equal cost of revenue; the filing reports no gross profit. Revenue in the prior-year quarter was zero.
- Nine-month net loss narrowed to $19.29 million from $21.89 million, while third-quarter net loss was slightly higher than the prior-year quarter’s $7.31 million.
- Nine-month R&D expense fell 20% and G&A expense fell 13%, primarily reflecting completion of the VISION-2 study, lower professional fees and lower stock-based compensation. Interest expense increased substantially.
- Cash used in operations decreased to $17.51 million from $19.70 million for the first nine months of 2022. Financing included the August registered offering, ATM sales and additional Avenue debt.
Outlook, risks and unusual items
- Going concern: Management states that recurring revenue is not material, the company remains unprofitable, and substantial doubt exists about its ability to continue as a going concern for at least one year after issuance of the financial statements. Continued operations depend on additional capital, licensing or other transactions; absent funding, the company may need to curtail R&D or reduce costs.
- Commercial outlook: Management expects early Mydcombi commercialization to generate flat gross margins until the second-generation Optejet is introduced and production is scaled. It expects broader launch activity in 2024 as internal manufacturing capabilities come online.
- Pipeline: The company’s stated goal was to file a MicroLine NDA by the end of 2024, subject to manufacturing registration batches and stability testing.
- Financing and dilution: The August 2023 offering generated approximately $10.9 million net cash proceeds and included common shares and warrants. Avenue provided an additional $5.0 million of proceeds; the loan agreement matures November 1, 2025, with interest-only payments extended through May 2024. The company also repriced and extended existing warrants, recording $1.74 million of non-cash offering costs.
- Contingency: Clinical supply product from a Gen 1.0 device was identified as defective and is expected to be returned for replacement or rework. The estimated loss range is $400,000–$600,000; $400,000 was accrued, with the final amount not yet determined.
- Formosa license: The company paid $2.0 million upfront (cash and stock) and may owe up to $4 million in development milestones and $80 million in sales milestones.
- The filing reports no material legal proceedings and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Whether the Mydcombi launch gains commercial traction and when manufacturing scale-up can support broader sales and improved margins.
- Cash burn, available funding and the timing and terms of any additional financing, licensing or other capital transactions.
- Debt repayment requirements, interest costs and potential dilution from outstanding warrants, options and other equity awards.
- The final quantity and cost of defective clinical supplies returned or reworked, compared with the recorded $400,000 accrual.
- FDA review status and milestone conditions for the Formosa-licensed product, and progress toward the company’s stated MicroLine filing goal.